Filing Analysis
NeOnc Technologies Holdings announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, an oral conjugate for aggressive brain tumors.
📋 Key Facts
- IND status granted by the Department of Health – Abu Dhabi (DOH) on June 16, 2026.
- The drug candidate is NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate.
- The target indication is aggressive brain tumors.
NeOnc Technologies Holdings entered into a Securities Purchase Agreement on June 10, 2026, to sell up to $5,000,000 of Series A Convertible Preferred Stock to accredited investors. The offering includes complex conversion terms and a redemption mechanism that can lead to significant common stock dilution.
🚩 Red Flags
- Death-spiral potential: The conversion price is set at a 20% discount to the lowest closing price of the preceding 5 days, which often leads to predatory dilution in micro-cap stocks
- Multiple 8-K items: The filing triggers Items 1.01, 3.02, 3.03, 5.03, and 9.01
- Complex redemption/conversion structure: The 'conversion only if not redeemed' clause creates an incentive for the company to avoid redemption to prevent dilution, or for investors to force conversion if the stock price drops
📋 Key Facts
- Aggregate offering amount: up to $5,000,000
- Security: Series A Convertible Preferred Stock (up to 6,000 shares)
- Purchase price: $833.34 per share
- Stated value: $1,000 per share
- Conversion Price: 80% of the lowest closing price of common stock during the 5 trading days prior to conversion (floor price of $1.00)
- Redemption: Company can redeem shares within 4 months (with two 1-month extension options), adding $50 per share per extension
- Conversion Trigger: Conversion is only available if the Company elects NOT to redeem the shares by the deadline
NeOnc Technologies Holdings, Inc. issued a press release on May 18, 2026, reporting its financial results for the first quarter. The filing follows standard disclosure protocols under Items 2.02 and 7.01 for quarterly earnings updates.
📋 Key Facts
- The company reported Q1 financial results on May 18, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The press release is included as Exhibit 99.1.
- The filing was signed by Amir Heshmatpour, CEO, President, and Executive Chairman.
NeOnc Technologies Holdings, Inc. entered into its fourth Securities Purchase Agreement of 2026, raising approximately $2 million through the sale of 277,777 shares and warrants to a single investor. The proceeds are earmarked for NEO216 preclinical trials, continuing a series of private placements that have raised over $15 million since January.
🚩 Red Flags
- Frequent, piecemeal financing (four separate agreements in four months) suggests a high cash burn rate or difficulty securing a single large-scale funding round.
- Potential for significant dilution from the issuance of warrants with a $9.00 exercise price.
- The offering terminates on April 30, 2026, indicating a narrow window for the remaining 406,694 shares in this tranche.
📋 Key Facts
- Sale of 277,777 shares of common stock at $7.20 per share on April 20, 2026.
- Issuance of 277,777 five-year warrants with an exercise price of $9.00 per share.
- Gross proceeds of approximately $2,000,000 from the latest closing.
- This represents the fourth separate Securities Purchase Agreement since January 29, 2026.
- Total capital raised across the series of agreements exceeds $15 million from multiple institutional and private investors.
- Proceeds are specifically designated to fund NEO216 preclinical trials.
NeOnc Technologies Holdings, Inc. announced that its Chairman and CEO, Amir Heshmatpour, purchased approximately $300,000 of the company's common stock. The company also used the announcement to provide additional context regarding operating expense increases reported in its 2025 Annual Report.
🚩 Red Flags
- The need to issue a press release to provide 'additional context' for operating expenses in a previously filed 10-K suggests potential investor concern regarding cost management or reporting clarity.
📋 Key Facts
- Chairman and CEO Amir Heshmatpour purchased approximately $300,000 worth of NTHI stock during the week of April 7-14, 2026.
- The filing provides clarification on year-over-year operating expense changes reported in the Form 10-K filed on March 31, 2026.
- The disclosure was made under Item 7.01 (Regulation FD) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
NeOnc Technologies Holdings, Inc. has established an at-the-market (ATM) equity program to sell up to $75 million of common stock. The sales will be conducted through BTIG, LLC and A.G.P./Alliance Global Partners at a 3% commission rate.
🚩 Red Flags
- Potential for significant shareholder dilution if the full $75 million ATM facility is utilized, especially for a micro-cap company.
📋 Key Facts
- Entered into an Equity Distribution Agreement on April 10, 2026, with BTIG, LLC and A.G.P./Alliance Global Partners.
- The program allows for the sale of up to $75,000,000 in common stock from time to time.
- The company will pay a commission of 3.0% of the gross proceeds to the placement agents.
- The offering is conducted under a Form S-3 registration statement (File No. 333-294845) which became effective on April 9, 2026.
- The company has no obligation to sell any shares and can suspend or terminate the agreement at any time.
NeOnc Technologies Holdings, Inc. (NTHI) filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were initially disclosed via a press release on April 1, 2026, and formally reported under Items 2.02 and 7.01.
📋 Key Facts
- Reported financial results for Q4 and full year ended December 31, 2025
- Press release issued on April 1, 2026
- Filing signed by CEO Amir Heshmatpour on April 3, 2026
- Common stock par value is $0.0001
NeOnc Technologies entered into its third Securities Purchase Agreement (SPA) since January 2026, raising $1 million through a private placement of 138,889 shares and warrants. This transaction is part of a series of offerings intended to sell up to 2,222,222 shares at $7.20 per share for working capital purposes.
🚩 Red Flags
- Serial private placements: Three separate Securities Purchase Agreements within a three-month period (Jan, Feb, March 2026).
- High frequency of small capital raises suggests immediate liquidity needs for working capital.
- Potential dilution from 1:1 warrant coverage at a $9.00 exercise price.
📋 Key Facts
- Entered into a third SPA on March 20, 2026, to sell remaining shares from a 2,222,222 share authorization.
- Raised $1,000,000 in the initial closing of this third SPA from one investor.
- Securities issued include 138,889 shares of common stock and five-year warrants to purchase 138,889 shares.
- Purchase price set at $7.20 per share with a warrant exercise price of $9.00.
- Previous closings under two prior SPAs in Jan/Feb 2026 raised approximately $12.07 million.
- The company must file a resale registration statement within 10 days of filing its 2025 Form 10-K.
NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer, effective March 12, 2026. Mr. Choi, a CPA with experience at Blythe Global Advisors and Big 4 firms, will oversee the company's accounting and financial reporting infrastructure.
📋 Key Facts
- David Choi appointed as Chief Accounting Officer (CAO) effective March 12, 2026.
- Base salary set at $162,500 per year.
- Granted 170,000 restricted shares, with 53,333 vesting immediately on the start date.
- Remaining equity includes 58,333 shares vesting after one year and 58,334 shares subject to performance-based metrics.
- Mr. Choi previously served as a Director at Blythe Global Advisors from 2021 to 2026.
NeOnc Technologies Holdings, Inc. announced clinical data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212. The company conducted an investor conference call on March 4, 2026, to discuss the results and provided a transcript and presentation as exhibits.
📋 Key Facts
- Announced data from Phase 1/2 clinical trial for NEO212 on March 4, 2026.
- The data pertains specifically to the dose-escalation portion of the trial.
- Hosted an investor conference call and provided a transcript (Exhibit 99.3) and presentation (Exhibit 99.2).
- The filing is made under Item 7.01 (Regulation FD Disclosure).
NeOnc Technologies Holdings settled a long-standing legal dispute with Fox Infused, LLC regarding the termination of an IP license and supply agreement. The company paid a total of $737,920.77, which included the original $600,000 settlement amount plus $137,920.77 in interest.
🚩 Red Flags
- Significant delay in settlement payment, occurring nearly two years after the March 2024 deadline
- High interest penalty of approximately 23% ($137,920.77) relative to the $600,000 principal
📋 Key Facts
- NeOnc terminated an Intellectual Property License and Supply Agreement with Fox Infused on April 25, 2023
- Fox Infused initiated litigation in June 2023, which subsequently moved to arbitration
- A settlement was reached requiring a $600,000 payment by March 31, 2024, or the closing of an IPO
- Payment was finally made on February 27, 2026, totaling $737,920.77
- The final payment included $137,920.77 in accrued interest due to the payment delay
NeOnc Technologies Holdings, Inc. entered into a new Securities Purchase Agreement on February 24, 2026, to raise capital through a private placement of common stock and warrants. This follows a previous January 2026 offering, with the current closing raising approximately $1.45 million from four investors.
🚩 Red Flags
- Frequent capital raises: The company conducted two separate offerings within a one-month span (January and February 2026), suggesting high cash burn.
- Dilutive impact: The issuance of shares and warrants at $7.20 and $9.00 respectively will dilute existing shareholders.
- Reliance on private placements (PIPEs) for working capital.
📋 Key Facts
- The company issued 201,390 shares of common stock at a price of $7.20 per share.
- The company issued 201,390 five-year warrants with an exercise price of $9.00 per share.
- The initial closing of this specific agreement on February 25, 2026, resulted in gross proceeds of $1,450,004.
- This follows a January 2026 offering that raised approximately $10.62 million.
- The company committed to filing a resale registration statement within 10 days of filing its 2025 Annual Report on Form 10-K.
- The offering terminated on February 28, 2026.
NeOnc Technologies Holdings announced an upcoming investor conference call and webcast scheduled for March 4, 2026. The company intends to present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial.
📋 Key Facts
- Investor call and webcast scheduled for March 4, 2026, at 9:00 a.m. ET.
- Presentation will cover initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.
- The disclosure was made under Item 7.01 (Regulation FD) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.